TY - JOUR
T1 - Effectiveness of medical supportive team for outpatients treated with sorafenib
T2 - A retrospective study
AU - Kajizono, Makoto
AU - Aoyagi, Megumu
AU - Kitamura, Yoshihisa
AU - Sendo, Toshiaki
N1 - Publisher Copyright:
© 2014 Kajizono et al.; licensee BioMed Central.
PY - 2015/2/18
Y1 - 2015/2/18
N2 - Background: It is well known that molecular-targeted drugs, of which sorafenib (Nexavar®) is one, differ from previous anticancer drugs and cause various unusual adverse drug reactions. Treatment with sorafenib causes adverse drug reactions such as hand-foot skin reactions, hypertension, and diarrhea. Physicians spend a lot of time monitoring adverse drug reactions to sorafenib in outpatients. As such, at Okayama University Hospital, pharmacists and nurses have organized a medical supportive team to help physicians in this regard. However, the effectiveness of interventions for sorafenib-treated outpatients by this medical supportive team remains unclear. The purpose of this study was thus to clarify the effectiveness of interventions for sorafenib-treated outpatients by this medical supportive team. Methods: We retrospectively studied 70 outpatients treated with sorafenib between May 2009 and December 2012 at Okayama University Hospital. These outpatients were classified into two groups, an intervention group (31 outpatients) and a non-intervention group (39 outpatients). We compared the duration of sorafenib treatment between these groups. Results: The duration of treatment with sorafenib was significantly longer in the intervention group than in the non-intervention group. No outpatients in the intervention group discontinued sorafenib due to adverse drug reactions such as hand-foot skin reactions or diarrhea. Conclusion: The duration of sorafenib treatment was significantly longer in the intervention group than in the non-intervention group. Our findings suggest that interventions by the medical supportive team consisting of health care professionals were effective in preventing the discontinuation of sorafenib.
AB - Background: It is well known that molecular-targeted drugs, of which sorafenib (Nexavar®) is one, differ from previous anticancer drugs and cause various unusual adverse drug reactions. Treatment with sorafenib causes adverse drug reactions such as hand-foot skin reactions, hypertension, and diarrhea. Physicians spend a lot of time monitoring adverse drug reactions to sorafenib in outpatients. As such, at Okayama University Hospital, pharmacists and nurses have organized a medical supportive team to help physicians in this regard. However, the effectiveness of interventions for sorafenib-treated outpatients by this medical supportive team remains unclear. The purpose of this study was thus to clarify the effectiveness of interventions for sorafenib-treated outpatients by this medical supportive team. Methods: We retrospectively studied 70 outpatients treated with sorafenib between May 2009 and December 2012 at Okayama University Hospital. These outpatients were classified into two groups, an intervention group (31 outpatients) and a non-intervention group (39 outpatients). We compared the duration of sorafenib treatment between these groups. Results: The duration of treatment with sorafenib was significantly longer in the intervention group than in the non-intervention group. No outpatients in the intervention group discontinued sorafenib due to adverse drug reactions such as hand-foot skin reactions or diarrhea. Conclusion: The duration of sorafenib treatment was significantly longer in the intervention group than in the non-intervention group. Our findings suggest that interventions by the medical supportive team consisting of health care professionals were effective in preventing the discontinuation of sorafenib.
KW - Adverse drug reactions
KW - Hand-foot skin reactions
KW - Hepatocellular carcinoma
KW - Medical supportive team
KW - Outpatient
KW - Renal cell carcinoma
KW - Sorafenib
UR - http://www.scopus.com/inward/record.url?scp=85011897622&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85011897622&partnerID=8YFLogxK
U2 - 10.1186/s40780-014-0005-0
DO - 10.1186/s40780-014-0005-0
M3 - Article
AN - SCOPUS:85011897622
VL - 1
JO - Journal of Pharmaceutical Health Care and Sciences
JF - Journal of Pharmaceutical Health Care and Sciences
SN - 2055-0294
IS - 1
M1 - 6
ER -